Statements (59)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:Novavax
|
| gptkbp:affiliated_with |
gptkb:WHO
|
| gptkbp:benefits |
preventing Zika virus infection
|
| gptkbp:challenges |
public perception
funding limitations logistical issues regulatory hurdles scientific hurdles |
| gptkbp:clinical_trial |
gptkb:2016
ongoing Phase 1 Phase 2 Phase 3 |
| gptkbp:developed_by |
gptkb:Zika_virus
|
| gptkbp:developer |
uncertain
|
| gptkbp:focus_area |
tropical regions
|
| gptkbp:healthcare |
potentially significant
|
| https://www.w3.org/2000/01/rdf-schema#label |
Zika vaccine
|
| gptkbp:investment |
global
travelers endemic regions |
| gptkbp:is_effective_against |
under investigation
|
| gptkbp:is_vulnerable_to |
gptkb:vaccine
government initiatives multiple ongoing academic studies field trials safety assessments collaborative efforts international studies clinical evaluations DNA vaccine inactivated live attenuated private sector research efficacy assessments immunogenicity assessments |
| gptkbp:manager |
injection
|
| gptkbp:manufacturer |
various pharmaceutical companies
|
| gptkbp:partnerships |
international collaborations
|
| gptkbp:public_awareness |
increasing
|
| gptkbp:receives_funding_from |
grants
donations crowdfunding government and private sector |
| gptkbp:regulatory_compliance |
pending
|
| gptkbp:research_areas |
various
|
| gptkbp:research_focus |
safety
efficacy immunogenicity |
| gptkbp:side_effect |
to be determined
|
| gptkbp:status |
in development
|
| gptkbp:symptoms |
Zika virus symptoms
|
| gptkbp:target_audience |
pregnant women
|
| gptkbp:targets |
mosquito-borne disease
|
| gptkbp:transmission |
reducing transmission
|